Assembly Biosciences (STU:V7B) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 11, 2026)


STU:V7B Assembly Biosciences Inc STU:V7B
31 GF Score
Price €24.00
GF Value €17.38
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Assembly Biosciences's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

STU:V7B vs CTNM, PRTA, RGNX: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Assembly Biosciences's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assembly Biosciences Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Margin of Safety % (DCF Dividends Based) falls into.


STU:V7B
31GF Score
Assembly Biosciences Inc STU:V7B
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Assembly Biosciences (STU:V7B) Overvalued in 2026?

Based on GuruFocus' analysis, Assembly Biosciences stock appears to be overvalued. The current stock price of €24.00 is trading 38.1% above its estimated GF Value™ of €17.38. GuruFocus considers Assembly Biosciences to be Significantly Overvalued.

Key valuation signals for STU:V7B:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €17.38 vs. price of €24.00 (38.1% above fair value)
  • GF Score™: 31/100 with 3 warning signs

No single metric tells the full story. See the STU:V7B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Assembly Biosciences Business Description

Other Exchanges ASMB:USA
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score

Get the complete analysis for STU:V7B

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.00
Price
€17.38
GF Value